Roivant stock jumps as lung drug meets mid-stage goal
Roivant Sciences’ experimental mosliciguat met the mid-stage trial’s main goal for patients with high blood pressure in the arteries of the lungs and heart, prompting a surge in its shares.
Roivant Sciences stock surged after the biotech said Tuesday that its experimental treatment met the mid-stage trial’s main goal for patients with high blood pressure in arteries of the lungs and heart. Roivant has been evaluating mosliciguat as a first-of-its-kind treatment for the condition.